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Treatment of subclinical hypothyroidism does not 
affect bone mass as determined by dual-energy X-ray 
absorptiometry, peripheral quantitative computed 
tomography and quantitative bone ultrasound  
in Spanish women
Juan D. Pedrera-Zamorano, Raul Roncero-Martin, Julian F. Calderon-Garcia,  
Mercedes Santos-Vivas, Vicente Vera, Mariana Martínez-Alvárez, Purificación Rey-Sanchez
A b s t r a c t
Introduction: The results of studies examining the influence of subclinical 
hypothyroidism (SCH) and levothyroxine (L-T4) replacement therapy on bone 
have generated considerable interest but also controversy. The present re-
search aims to evaluate the effects of L-T4 treatment on different skeletal 
sites in women. 
Material and methods: A group of 45 premenopausal (mean age: 43.62 ±6.65 
years) and 180 postmenopausal (mean age: 59.51 ±7.90 years) women with 
SCH who were undergoing L-T4 replacement therapy for at least 6 months 
were compared to 58 pre- and 180 postmenopausal women with SCH (un-
treated) matched for age. The mean doses of L-T4 were 90.88 ±42.59 µg/day 
in the premenopausal women and 86.35 ±34.11 µg/day in the postmeno-
pausal women. Bone measurements were obtained using quantitative bone 
ultrasound (QUS) for the phalanx, dual-energy X-ray absorptiometry (DXA) 
for the lumbar spine and hip, and peripheral quantitative computed tomog-
raphy (pQCT) for the non-dominant distal forearm. 
Results: No differences were observed between patients and untreated con-
trols in these bone measurements except in the bone mineral density (BMD) 
of the spine (p = 0.0214) in postmenopausal women, which was greater in 
treated women than in untreated controls. 
Conclusions: Our results indicate that adequate metabolic control through 
replacement treatment with L-T4 in pre- and postmenopausal women does 
not affect bone mass. 
Key words: subclinical hypothyroidism, levothyroxine, bone mineral 
density, premenopausal, postmenopausal.
Introduction
Subclinical hypothyroidism (SCH) is a common problem, especially in 
middle-aged and older adults [1]. Its prevalence varies from 3% to 15%, 
depending on age, sex and the population under study and the diagnos-
tic criteria used [2]. Subclinical hypothyroidism may progress to overt 
hypothyroidism in approximately 2–5% of cases annually [3]. The prev-
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alence of this condition increases with age and 
is greater in women than in men [4]. Subclinical 
hypothyroidism is defined as a serum concentra-
tion of thyroid-stimulating hormone (TSH) above 
the upper limit of the reference range when the 
concentration of serum-free T4 (FT4) is within the 
reference range [5].
Thyroid hormones are key regulators of bone 
formation and remodeling. Thyroid hormone T3 
stimulates osteoblast activity both directly and 
indirectly through numerous growth factors and 
cytokines [6]. It also directly stimulates osteoclast 
differentiation [7], although it is unclear whether 
T3 can act on osteoblasts to indirectly stimulate 
osteoclastic bone resorption [8].
Physiological variation in thyroid status is re-
lated to bone mineral density (BMD) and fracture 
in healthy, euthyroid, postmenopausal women. 
Higher FT4 and free T3 (FT3) levels are associated 
with reduced BMD, and higher FT4 levels are as-
sociated with increased bone loss at the hip [9]. 
Abe et al. [10] found evidence for direct effects of 
TSH on components of skeletal remodeling, os-
teoblastic bone formation, and osteoclastic bone 
resorption, and these effects were mediated via 
the TSH receptor present on osteoblast and os-
teoclast precursors. Other studies suggested that 
TSH exerts a bone-protective action by negatively 
regulating osteoclastogenesis [11]. A recent study 
in postmenopausal women with normal TSH lev-
els showed a  favorable bone status compared 
to those with low TSH levels irrespective of the 
FT4 level [12]. This result is consistent with the 
view that TSH plays a role in the preservation of 
bone after menopause [13]. Other studies in post-
menopausal women with SCH suggest that the 
elevation of serum TSH concentration affects not 
bone markers but bone structure as assessed by 
bone quantitative ultrasound (QUS) in the calca-
neus [14].
Treatment with L-T4 has been shown to be effec-
tive in improving alterations produced in patients 
with SCH such as cognitive function [15]; howev-
er, the long-term effect of replacement treatment 
with levothyroxine (L-T4) on bones has produced 
controversial results. Some studies found that 
treatment with replacement doses of L-T4 result-
ed in a decrease in bone density [16, 17], while in 
others this treatment resulted in accelerated bone 
loss, although the absolute values were not in the 
range that is typical of osteoporosis [18]. Frank-
lyn et al. [19] found that thyroxine alone does not 
have a significant effect on BMD. 
The purpose of this study was to investigate 
the effect of chronic treatment with replacement 
L-T4 on bone in pre- and postmenopausal wom-
en with SCH and to compare the results obtained 
with women with untreated SCH. We evaluated 
bone status using quantitative bone ultrasound 
(QUS) for the phalanx, dual-energy X-ray absorp-
tiometry (DXA) for the lumbar spine and hip, 
and quantitative bone ultrasound (pQCT) for the 
non-dominant distal radius. Using these three dif-
ferent techniques, our study enhances our under-
standing of the affected bone compartments and 
possible changes in bone quality in women.
Material and methods
We studied 225 women, including 45 premeno-
pausal (mean age: 43.62 ±6.65 years) and 180 
postmenopausal (mean age: 59.51 ±7.90 years) 
women, with SCH who were on L-T
4 replacement 
therapy for at least 6 months at a  mean dose 
of 90.88 ±42.59 µg/day for the premenopausal 
women and 86.35 ±34.11 µg/day for the post-
menopausal women. Inclusion criteria were age 
over 18, being in treatment with thyroid hormone 
replacement for at least six months (for the treat-
ment group and not receiving such treatment for 
the control group), and having TSH levels higher 
than 4.5 mU/l and FT4 levels in the normal range 
(0.8–1.2 ng/dl) [1]. The exclusion criteria included 
clinical osteoporosis and routine medication that 
interfered with vitamin D or bone metabolism.
As controls, a  group of 58 premenopausal 
women (mean age: 44.77 ±6.82 years) and 180 
postmenopausal women (mean age: 58.75 ±7.92 
years) with untreated SCH who were similar in 
race and geographical location were recruited by 
random digit dialing. 
All the women were residing in the urban area 
of the health district of Caceres, Spain. The post-
menopausal women had primary or secondary 
studies and the premenopausal women second-
ary or university studies. The majority of them 
were married, had children, and their social status 
was average. None of the participants had dietary 
restrictions, neurological impairment, or physical 
disabilities, and their medical histories showed no 
presence of low-trauma fractures. All participat-
ing subjects gave written informed consent, and 
the research project was approved by the Ethical 
Review Committee at the Hospital “San Pedro de 
Alcántara” of Cáceres, and the Office for Protec-
tion from Research Risks at the University of Ex-
tremadura in accordance with the Helsinki Decla-
ration of 1975.
We took a complete medical history and phys-
ically examined each subject before she was en-
rolled in the study. No women in the study were 
taking medications that would interfere with 
calcium metabolism (corticoids, oral anticoagu-
lants, antipsychotics, etc.), with the exception of 
hormone replacement therapy with L-T
4. All wom-
en led active lives but did not regularly practice 
sports. Alcohol intake was sporadic, not exceeding 
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100 ml/day in any case. Only 5% of the women 
smoked, and not more than 10 cigarettes per day. 
Height was measured using a  Harpenden sta-
diometer with a  mandible plane parallel to the 
floor, and weight was measured using a biomed-
ical precision balance. Both measurements were 
determined with the subjects wearing only light 
clothing and no shoes. The body mass index (BMI) 
was calculated as weight in kilograms divided by 
the square of the height in meters (BMI (kg/m2)). 
Body composition was studied by means of bio-
electrical impedance analysis (BIA) using a  body 
composition analyzer (BC-418MA, TANITA, Tokyo, 
Japan). Food intake was quantified using dietet-
ic scales, measuring cups, and spoons based on 
7 days of diet record [20]. The intake of nutrients 
of all groups of women was consistent with the 
recommendations given by their government au-
thorities (i.e., the recommended dietary allowanc-
es (RDA) given by European Union and Spanish 
authorities), with the exception of proteins, which 
were higher than the RDA, due to being in an area 
of high protein intake [21, 22].
Bone measurements
An ultrasound was performed on the 2nd to the 
5th proximal phalanx of the nondominant hand us-
ing a DBM Sonic Bone Profiler (IGEA, Capri, Italy).
The femoral neck and L2-L4 spine BMDs were 
measured by DXA (Norland XR-800, Norland Inc., 
Fort Atkinson, USA) and are expressed as the 
amount of mineral (g) divided by the area scanned 
(cm2).
The pQCT measurements were performed on 
the nondominant distal forearm using a  Stratec 
XCT-2000 device (Stratec Medizintechnik, Pfor-
zheim, Germany). 
Analytical studies
All subjects underwent biochemical measure-
ments of blood glucose, transaminase, g-glutamyl 
transferase (GGT), creatinine, calcium, phospho-
rus, total protein, bilirubin, alkaline phosphatase, 
and tartrate-resistant acid phosphatase (TRAP) 
levels, and coagulation study; and TSH and FT4 
serum concentrations were measured by electro-
chemiluminescence immunoassay (ECLIA) using 
a  commercial kit (Roche Diagnostics). For each 
subject, the calcium level was corrected for pro-
teins, and normal calcium excretion and tubular 
phosphatase resorption were confirmed by con-
ducting a  biochemical study on a  24-hour urine 
sample.
Smoking; coffee, tea or alcohol intake; and 
exercise were not permitted during the 24 h be-
fore testing. We collected urine samples on the 
morning of testing after an overnight fast. Venous 
blood samples for hematological and biochemi-
cal studies were also obtained when the subjects 
were fasting (at 8:00 a.m.).
The blood samples were centrifuged, and the 
serum was stored at –20°C until analysis. We mea-
sured the concentrations of biochemical species 
in the serum using an Hitachi automated analyzer 
system 902 (Roche, Manheim, Germany) and the 
24-hour urinary calcium excretion by atomic ab-
sorption spectroscopy using a Perkin Elmer model 
5000 spectrophotometer (Perkin Elmer, Norfolk, 
CT, USA).
The baseline blood chemistry, amplitude-de-
pendent speed of sound (Ad-SoS), DXA, and pQCT 
measurements were obtained in the same session 
and at an ambient temperature of 22°C.
Statistical analysis
All values are expressed as the mean ± SD. We 
confirmed the normal distribution of the data 
by calculating the skewness and kurtosis before 
applying standard tests. We compared the pa-
rameters (continuous variables) for each group 
(nominal variables) using the t test, an analysis of 
variance and covariance to determine the effects 
of the nominal variables. We also used single and 
multiple stepwise regressions and partial correla-
tions (adjusted for age) to examine the relation-
ships between continuous variables. A  value of 
p < 0.05 was required for statistical significance. 
We processed the data using the StatView 5.01 
statistical package (SAS Institute Inc., Cary, NC, 
USA).
Results
For the biological, anthropometric and bio-
chemical variables (Table I), we found no signifi-
cant differences between treated and untreated 
controls in premenopausal women. In postmeno-
pausal women, the age of menarche was signifi-
cantly lower in the treatment group than in the 
controls (p = 0.0083).
The results of the bone status analysis are 
shown in Table II. The only comparison that yield-
ed significant differences was the comparison 
of the L2-L4 BMD between the postmenopausal 
treated patients and matched untreated controls 
(p = 0.0214), and BMD was higher in the treated 
women.
In the stepwise regression, we used the bone 
measurements as dependent variables and the 
other biological variables, anthropometric factors 
and thyroid function values as independent vari-
ables. In the group of premenopausal women on 
L-T
4 replacement therapy, the DXA measurements 
of the neck BMD and L2–L4 BMD were negative-
ly correlated with age (β = –0.009, p = 0.0136; 
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β = –0.007, p = 0.0432, respectively). In the pQCT 
experiments, the total density and cortical + 
subcortical density were negatively correlated 
with age of menarche (β = –19.944, p = 0.0113; 
β = –32.165, p = 0.0116, respectively). No vari-
able showed an association with bone measure-
ments in the untreated SCH group. No variable 
showed an association with Ad-SoS in the stud-
ied groups.
In the group of postmenopausal women on L-T
4 
replacement therapy, the QUS parameter Ad-SoS 
was negatively correlated with age (β = –4.245, p = 
0.0003). The neck BMD and L2-L4 BMD were nega-
tively correlated with years since menopause (YSM) 
(β = –0.006, p = 0.0012; β = –0.006, p = 0.0105, 
respectively) and positively correlated with BMI 
(β = 0.008, p < 0.0001; β = 0.008, p = 0.0016, re-
spectively). In the untreated group, the Ad-SoS 
was negatively correlated with age (β = –3.857, 
p = 0.0106), and the neck BMD and L2–L4 BMD 
were negatively correlated with YSM (β = –0.005, 
p = 0.0191; β = –0.010, p = 0.0009, respective-
ly) and positively correlated with BMI (β = 0.007, 
p < 0.0001; β = 0.006, p = 0.0369, respectively). No 
variable was associated with any pQCT measure in 
the studied groups.
There are no significant differences in terms 
of the presence of osteoporosis and osteopenia 
between the total groups of women with treat-
ed SCH and untreated SCH; thus, in the group of 
women with SCH, 8% (n = 18) presented osteo-
porosis, 30.66% (n = 69) osteopenia, and 61.33% 
(n = 138) were normal according to densitometry; 
in the control group, 9.66% (n = 23) had osteo-
porosis, 35.71% (n = 85) osteopenia, and 54.62% 
(n = 130) were normal according to densitometry.
Discussion
Our study evaluated the effect of at least 
6 months of L-T
4 replacement therapy on bone 
mass in women with SCH compared to control 
women of the same age with SCH and without 
treatment. To this end, we used three techniques 
to determine bone status, QUS, DXA and pQCT, 
with the purpose of evaluating cortical and tra-
becular bone. 
We found no significant differences in the 
bone parameters between premenopausal wom-
en on L-T
4 replacement therapy and the untreated 
controls. The effect of L-T
4 treatment on BMD in 
premenopausal women is uncertain. Saggese et 
al. [23], who studied a group of thirteen adoles-
Table I. Biological and anthropometric characteristics, thyroid function, and dose of levothyroxine in the groups  
of women studied
Parameter Premenopausal Postmenopausal RDA
Treated SCH  
(n = 45)
Untreated SCH 
(n = 58)
Treated SCH  
(n = 180)
Untreated SCH 
(n = 180)
Age [years] 43.62 ±6.65 44.77 ±6.82 59.51 ±7.90 58.75 ±7.92
Age of menarche [years] 12.46 ±1.32 12.74 ±1.54 12.61 ±1.50* 13.04 ±1.55
Years since menopause 10.91 ±7.91 9.87 ±8.13
BMI [kg/m2] 27.02 ±6.39 26.58 ±4.39 28.53 ±4.55 27.75 ±4.27
Trunk lean mass [kg] 24.42 ±2.56 23.93 ±2.03 23.75 ±2.09 23.39 ±2.00
Trunk fat mass [kg] 11.23 ±5.48 11.82 ±4.22 13.09 ±1.10 12.19 ±3.93
Trunk fat % 30.14 ±8.64 31.93 ±7.07 34.69 ±6.63 33.48 ±6.54
T4 dose/day [µg] 90.88 ±42.59 86.35 ±34.11
TSH [mU/l] 1.38 ±0.29 6.72 ±1.42* 1.19 ±0.17 8.8 ±1.7*
FT4 [ng/dl] 1.09 ±1.10 0.98 ±0.74 1.18 ±0.54 1.19 ±0.21
Calories/day 2245.84 ±643.28 2076.56 ±410.82 2100.48 ±616.66 2172.07 ±580.24 2265
Carbohydrates [g] 271.56 ±104.77 273.33 ±73.97 260.89 ±94.13 265.73 ±80.86 330
Fat [g] 86.58 ±30.59* 71.51 ±19.50 74.99 ±30.93 80.12 ±32.49 90
Protein [g] 93.15 ±38.64 83.34 ±18.31 91.28 ±31.85 95.86 ±36.77 47
Protein/weight [g/kg] 1.44 ±0.65 1.27 ±0.34 1.36 ±0.55 1.48 ±0.61 0.8
Calcium [mg/day] 1045.27 ±453.92 1049.40 ±461.59 1061.71 ±450.89 1128.47 ±471.17 800
Phosphorus [mg/day] 1407.66 ±504.49 1338.88 ±356.17 1387.53 ±508.05 1487.48 ±571.46 800
BMI – Body mass index, RDA  – recommended dietary allowances, *p < 0.01, compared with the respective untreated group.
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cent SCH girls with a  median age of 13.4 years 
who were on long-term L-T4 therapy, evaluated 
L2-L4 BMD by DXA and found no adverse effect 
on BMD or bone turnover. Moreover, the attain-
ment of peak bone mass was not impaired. Larija-
ni et al. [24] studied a group of 50 premenopusal 
women reciving suppressive therapy with L-T4 for 
1 year and found no increased risk of osteoporosis 
using DXA. Greenspan et al. [25] observed mini-
mal changes in bone density in premenopausal 
women with physiological doses of L-T4. However, 
other studies showed a reduction of BMD in pre-
menopausal women receiving long-term L-T4 ther-
apy. Kung and Pun [16] studied 26 premenopausal 
women with Hashimoto’s thyroiditis and reported 
that the BMD of the spine was unaffected, but the 
BMD of the femoral neck was reduced. A similar 
effect was observed in women taking L-T4 sup-
pressive doses [26], in which excess exogenous 
thyroxine might predominantly deplete skeletal 
sites, and the BMD might be affected, particularly 
at the femoral neck, which is rich in cortical bone. 
A meta-analysis in 1996 [27] resulted in the con-
clusion that replacement therapy with L-T4 was 
associated with bone loss in the spine and hip in 
premenopausal women but not in postmenopaus-
al women, and this effect was more marked in cor-
tical bone than in trabecular bone. 
In our stepwise regression in premenopausal 
patients, the DXA variables were negatively cor-
related with age. Our group has previously report-
ed the negative effect of age on bone in premeno-
pausal women via ultrasound on the phalanx [28]. 
We also found a  negative relationship between 
the parameters of pQCT (total density and cortical 
+ subcortical density) and the age of menarche in 
the patients of this study, indicating that cortical 
density is affected by this biological variable. One 
study in 2008 [29] found that in young adult wom-
en, an age of menarche that was late but within 
the normal range was associated with a  deficit 
in cortical density. This result is consistent with 
our results, because those authors used DXA and 
pQCT to measure bone parameters and suggest-
ed that the estrogen exposure from the onset of 
sexual maturation to the end of growth influences 
the peak bone mass achieved. 
In postmenopausal women, replacement treat-
ment with L-T4 has been associated with a small 
but significant reduction in the BMD of the spine 
and hip. This negative effect on bones seems 
more pronounced in the cortical bone than in 
the trabecular bone [18]. Hadji et al. [18] studied 
a group of 156 women treated with replacement 
doses of L-T4 and indirectly evaluated bone mass 
using QUS at the heel; they observed a slight re-
duction in the ultrasound values. In our study of 
180 postmenopausal women treated with L-T4, 
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we observed no differences in the QUS measure-
ments of the phalanx between the treated pa-
tients and untreated controls. La Vignera et al. 
[30], in a  study of 99 postmenopausal women 
between 50 and 56 years of age and treated with 
L-T4 for 1 year, observed a slight but significant re-
duction in the BMD of the lumbar vertebrae mea-
sured by DXA, which was more pronounced in 
patients on suppressive treatment than in those 
who were not on this treatment and was associ-
ated with increased serum alkaline phosphatase 
levels and increased urinary excretion of hydroxy-
proline. However, other authors found no reduc-
tion in BMD in postmenopausal women with SCH 
who were on L-T4 treatment [31, 32], which is in 
agreement with our results at the lumbar spine 
and hip. 
The stepwise regression showed similar results 
in patients and controls. In QUS, Ad-SoS decreased 
with age in both patients and controls. The de-
crease in bone mass with age in postmenopaus-
al women is widely documented [28, 33], but it 
seems that YSM is a more important predictor of 
bone loss than chronological age [34, 35]. This 
conclusion agrees with our results, because the 
DXA parameters correlated negatively with YSM 
in all women. The BMI also showed a positive re-
lationship with the DXA parameters. Body mass 
index is often considered a  positive correlate of 
BMD, but the link between BMI and BMD has not 
yet been clarified. The possible mechanistic expla-
nations for the relationship between these phys-
iological parameters include the actions of gluco-
corticoids, growth and sex hormones, leptin, and 
inflammatory adipokines [36].
With regard to the anthropometric parameters 
in patients with SCH, replacement therapy with 
L-T4 not only improves the lipid profile but also 
decreases the BMI [37]. Our study confirms this 
effect, because there were no significant differ-
ences in the BMI or in the lipid profile (data not 
shown) between treated and untreated wom-
en in the premenopausal or postmenopausal 
groups. 
Few studies have used all three of these im-
portant techniques to assess bone mass, and 
none of them was related to treatment with L-T4. 
Moreover, research on the effects of long-term L-T4 
treatment has been conducted mainly on patients 
taking suppressive doses of L-T4. We consider 
these facts and the large number of participants 
in the current study to be the main strengths of 
our work.
In conclusion, our results indicate the absence 
of adverse effects due to L-T4 replacement therapy 
in the QUS of the phalanges, BMD of either the 
spine or the hip, and the pQCT in the non-domi-
nant distal radius in SCH-treated women. 
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